Supernus Pharmaceuticals (SUPN) Total Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Total Current Liabilities data on file, last reported at $373.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 32.71% year-over-year to $373.9 million in Q1 2026; TTM through Mar 2026 was $373.9 million, a 32.71% increase from a year earlier, with the FY2025 full-year figure at $338.2 million, up 15.65% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $373.9 million, up from $338.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for SUPN reached as high as $735.5 million in Q2 2022 and fell as low as $252.6 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $400.8 million across 5 years, with a median of $308.7 million in 2024.
• Across the five-year window, Total Current Liabilities surged 209.31% in 2022 and slumped 65.66% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $688.0 million in 2022, then slumped by 57.82% to $290.2 million in 2023, then increased by 0.76% to $292.4 million in 2024, then rose by 15.65% to $338.2 million in 2025, then climbed by 10.57% to $373.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $373.9 million in Q1 2026, $338.2 million in Q4 2025, and $330.6 million in Q3 2025.